Phosphoproteomic analysis identifies phospho-Threonine-17 site of phospholamban important in low molecular weight isoform of fibroblast growth factor 2-induced protection against post-ischemic cardiac dysfunction. (November 2020)
- Record Type:
- Journal Article
- Title:
- Phosphoproteomic analysis identifies phospho-Threonine-17 site of phospholamban important in low molecular weight isoform of fibroblast growth factor 2-induced protection against post-ischemic cardiac dysfunction. (November 2020)
- Main Title:
- Phosphoproteomic analysis identifies phospho-Threonine-17 site of phospholamban important in low molecular weight isoform of fibroblast growth factor 2-induced protection against post-ischemic cardiac dysfunction
- Authors:
- Manning, Janet R.
Wijeratne, Aruna B.
Oloizia, Brian B.
Zhang, Yu
Greis, Kenneth D.
Schultz, Jo El J. - Abstract:
- Abstract: Rationale: Among its many biological roles, fibroblast growth factor 2 (FGF2) protects the heart from dysfunction and damage associated with an ischemic attack. Our laboratory demonstrated that its protection against myocardial dysfunction occurs by the low molecular weight (LMW) isoform of FGF2, while the high molecular weight (HMW) isoforms are associated with a worsening in post-ischemic recovery of cardiac function. LMW FGF2-mediated cardioprotection is facilitated by activation of multiple kinases, including PKCalpha, PKCepsilon, and ERK, and inhibition of p38 and JNK. Objective: Yet, the substrates of those kinases associated with LMW FGF2-induced cardioprotection against myocardial dysfunction remain to be elucidated. Methods and results: To identify substrates in LMW FGF2 improvement of post-ischemic cardiac function, mouse hearts expressing only LMW FGF2 were subjected to ischemia-reperfusion (I/R) injury and analyzed by a mass spectrometry (MS)-based quantitative phosphoproteomic strategy. MS analysis identified 50 phosphorylation sites from 7 sarcoendoplasmic reticulum (SR) proteins that were significantly altered in I/R-treated hearts only expressing LMW FGF2 compared to those hearts lacking FGF2. One of those phosphorylated SR proteins identified was phospholamban (PLB), which exhibited rapid, increased phosphorylation at Threonine-17 (Thr17) after I/R in hearts expressing only LMW FGF2; this was further validated using Selected ReactionAbstract: Rationale: Among its many biological roles, fibroblast growth factor 2 (FGF2) protects the heart from dysfunction and damage associated with an ischemic attack. Our laboratory demonstrated that its protection against myocardial dysfunction occurs by the low molecular weight (LMW) isoform of FGF2, while the high molecular weight (HMW) isoforms are associated with a worsening in post-ischemic recovery of cardiac function. LMW FGF2-mediated cardioprotection is facilitated by activation of multiple kinases, including PKCalpha, PKCepsilon, and ERK, and inhibition of p38 and JNK. Objective: Yet, the substrates of those kinases associated with LMW FGF2-induced cardioprotection against myocardial dysfunction remain to be elucidated. Methods and results: To identify substrates in LMW FGF2 improvement of post-ischemic cardiac function, mouse hearts expressing only LMW FGF2 were subjected to ischemia-reperfusion (I/R) injury and analyzed by a mass spectrometry (MS)-based quantitative phosphoproteomic strategy. MS analysis identified 50 phosphorylation sites from 7 sarcoendoplasmic reticulum (SR) proteins that were significantly altered in I/R-treated hearts only expressing LMW FGF2 compared to those hearts lacking FGF2. One of those phosphorylated SR proteins identified was phospholamban (PLB), which exhibited rapid, increased phosphorylation at Threonine-17 (Thr17) after I/R in hearts expressing only LMW FGF2; this was further validated using Selected Reaction Monitoring-based MS workflow. To demonstrate a mechanistic role of phospho-Thr17 PLB in LMW FGF2-mediated cardioprotection, hearts only expressing LMW FGF2 and those expressing only LMW FGF2 with a mutant PLB lacking phosphorylatable Thr17 (Thr17Ala PLB) were subjected to I/R. Hearts only expressing LMW FGF2 showed significantly improved recovery of cardiac function following I/R ( p < 0.05), and this functional improvement was significantly abrogated in hearts expressing LMW FGF2 and Thr17Ala PLB ( p < 0.05). Conclusion: The findings indicate that LMW FGF2 modulates intracellular calcium handling/cycling via regulatory changes in SR proteins essential for recovery from I/R injury, and thereby protects the heart from post-ischemic cardiac dysfunction. Graphical abstract: Unlabelled Image Highlights: LMW FGF2 improves post-ischemic recovery of cardiac function. Phosphoproteomic/SRM mode identified SR proteins in LMW FGF2 cardioprotection. Threonine-17 site of PLB important for LMW FGF2 effect against ischemic dysfunction. LMW FGF2 improves post-ischemic recovery via multiple calcium handling proteins/genes. … (more)
- Is Part Of:
- Journal of molecular and cellular cardiology. Volume 148(2020)
- Journal:
- Journal of molecular and cellular cardiology
- Issue:
- Volume 148(2020)
- Issue Display:
- Volume 148, Issue 2020 (2020)
- Year:
- 2020
- Volume:
- 148
- Issue:
- 2020
- Issue Sort Value:
- 2020-0148-2020-0000
- Page Start:
- 1
- Page End:
- 14
- Publication Date:
- 2020-11
- Subjects:
- Phospholamban phosphorylation -- Ischemia-reperfusion injury -- Fibroblast growth factor -- Mass spectrometry -- Proteomics and genomics
5′I 5 min ischemia -- 60′I + 5′R 60 min ischemia +5 min reperfusion -- 60′I + 120′R 120 min reperfusion -- ANOVA analysis of variance -- CaMKIIa calcium camodulin kinase II -- CLXN calnexin -- CSQ calsequestrin -- XIC extracted ion chromatogram -- FGF2 fibroblast growth factor 2 -- FHF fibroblast growth factor homologous factor -- HMW high molecular weight -- I/R ischemia-reperfusion -- JP2 junctophilin-2 -- KO knockout -- LC liquid chromatography -- LMW low molecular weight -- MS mass spectrometry -- MI myocardial infarction -- PLB phospholamban -- RABA reductive alkylation by acetone -- RyR2 ryanodine receptor -- SR sarcoendoplasmic reticulum -- SERCA sarcoendoplasmic reticulum calcium ATPase -- SRM selected reaction monitoring -- Ser16 serine-16 -- Thr17 threonine-17 -- Tg transgenic
Cardiology -- Periodicals
Heart Diseases -- Periodicals
Molecular Biology -- Periodicals
Cardiologie -- Périodiques
Cardiology
Electronic journals
Periodicals
616.12 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00222828 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00222828 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/00222828 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.yjmcc.2020.08.006 ↗
- Languages:
- English
- ISSNs:
- 0022-2828
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5020.690000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14910.xml